Gw Pharmaceuticals Plc Ads (GWPH) 69.77 $GWPH
CannabisFN Weekly: Stock Move Lower as Valuations Start to Normalize
ACCESSWIRE - Mon May 12, 8:34AM CDT
WHITEFISH, MT / MAY 12, 2014 / The Marijuana Index(TM) moved lower last week, led by steep declines in CannaVEST Corp. (OTC: CANV) and modest declines in bellwethers like GW Pharmaceuticals plc (NASDAQ: GWPH) and MedBox Inc. (OTC: MDBX).
Research & Development Kick Into High Gear For Cannabis Based Medicine - New Collaboration Agreement For Development of Cannabis Based Skin Cancer Medicine
PR Newswire - Fri May 09, 7:50AM CDT
Marijuana & Cannabinoid Based Medicine industry continues to grow as companies forge ahead searching for new research and development, as well as expansion, opportunities: New Colombia Resources, Inc. (OTC: NEWC), GW Pharmaceuticals plc (NASDAQ: GWPH), Hemp, Inc. (OTC: HEMP), Nuvilex, Inc. (OTC: NVLX) and Tranzbyte Corporation (OTC: ERBB)
GW Pharmaceuticals to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
GlobeNewswire - Thu May 08, 11:00AM CDT
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group"
, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas, NV on Tuesday, 13 May, 2014 at 4:20 p.m. PT (1:20 p.m. ET). The conference will be held at the Encore at Wynn Las Vegas.
FDA approves GW drug trial
at Investor's Business Daily - Wed May 07, 6:00PM CDT
The biotech reported a rise in revenue in the 6 months ended March 31. It posted a loss in profit vs. a gain in the 6-month period a year ago. GW Pharmaceuticals (GWPH) got Investigational New Drug status from the FDA for a Phase 2/3 clinical trial...
Today’s Top Biotech Stories: Aegerion, GW, and Ariad Pharmaceuticals
Leo Sun, The Motley Fool - Motley Fool - Wed May 07, 8:11AM CDT
Let's take a closer look at three stocks -- Aegerion Pharmaceuticals , GW Pharmaceuticals , and Ariad Pharmaceuticals -- which could make waves across the health care sector this Wednesday morning. Aegerion slumps on weak earnings...
GW Pharmaceuticals plc Reports Second Quarter 2014 Financial Results and Operational Progress
GlobeNewswire - Wed May 07, 4:06AM CDT
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group" , a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial results for the second quarter and half year ended 31 March 2014.
GW Pharmaceuticals Receives Investigational New Drug (IND) From FDA for Phase 2/3 Clinical Trial of Epidiolex(R) in the Treatment of Dravet Syndrome
GlobeNewswire - Wed May 07, 4:06AM CDT
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group" , a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the Company has received confirmation from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug application (IND) is now open for Epidiolex in the treatment of Dravet Syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy. GW expects to commence a Phase 2/3 clinical trial in the second half of 2014.
BreedIT Corp: The Money is in the Seeds
ACCESSWIRE - Tue May 06, 8:52AM CDT
Whitefish, MT / May 6, 2014 / The U.S. cannabis industry is expected to grow more than five-fold over the next five years, from $2.2-2.6 billion in 2014 to an estimated $7.4-8.2 billion by 2018, according to new report by MMJ Business Daily. While growers and dispensaries will likely take the lion's share of the revenue, the highest margin opportunities may be in licensing the seeds used to grow specific optimized strains.
GW Pharmaceuticals Appoints Dr. Kenneth Sommerville as VP, Clinical Science
GlobeNewswire - Tue May 06, 1:00AM CDT
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group" , a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced the appointment of Kenneth Sommerville MD to the newly created position of VP, Clinical Science, based in the United States.
CannabisFN Weekly: New Rules for Edibles Signal Maturing Market
ACCESSWIRE - Mon May 05, 8:02AM CDT
Whitefish, MT / May 5, 2014 / The Marijuana Index™ moved about 8% higher over the past week, led by a 15% jump in GW Pharmaceuticals plc (NASDAQ: GWPH) shares. Last week, Morgan Stanley analysts rated the stock "overweight" with a $103.00 per share price target, which is significantly higher than the consensus price target of $54.43. Shares of many other cannabis stocks remained largely neutral throughout the week.
Earnings Results, Acquisitions, Drug Designations, Dividend Authorizations, and Licensing Agreements - Analyst Notes on AstraZeneca, Furiex, GW, Techne and Agenus
PR Newswire - Mon May 05, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding AstraZeneca PLC (NYSE: AZN), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX), GW Pharmaceuticals plc (NASDAQ: GWPH), Techne Corp. (NASDAQ: TECH) and Agenus Inc. (NASDAQ: AGEN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1869-100free.
Jim Cramer's Top Stock Picks: PNRA GWPH LOCK
at The Street - Sat May 03, 5:00AM CDT
Cramer has a taste for the improvements at Panera, is high on GW Pharmaceuticals and thinks LifeLock cheap stock is a steal.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri May 02, 7:24PM CDT
Today's move into the red caught investors by surprise because the economy seems to be improving. Here's what Cramer will be watching next week.
3 Stocks Spiking on Big Volume
at The Street - Thu May 01, 8:23AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
GW Pharmaceuticals to Report Q2 2014 and Half Year Financial Results and Host Conference Call on 7 May, 2014
GlobeNewswire - Tue Apr 29, 11:30AM CDT
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company" , a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 7 May, 2014 its second quarter and half year financial results for the period ending 31 March, 2014. GW will also host a conference call the same day at 1:00 p.m. BST (8:00 a.m. EDT).
Jim Cramer's Stop Trading: The Go-To Medical Marijuana Stock
at The Street - Tue Apr 29, 10:29AM CDT
A new study says medical marijuana has benefits for patients with multiple sclerosis, and Cramer says the go-to stock in this area is GW Pharmaceuticals.
Autism Patients Could Be Helped with Cannabis
at The Street - Tue Apr 29, 7:30AM CDT
GW Pharmaceuticals hasn't pursued the autism patient population with its cannabis drugs, but impatient parents may not want to wait.
NTRR Prepares to Bring New Products Online
Business Wire - Tue Apr 29, 4:00AM CDT
After extensive testing and feedback from potential distributors and users this month at mega-events Cannabis Cup and the Big Industry Show in Colorado, Neutra Corp. (OTCBB: NTRR) announced today that its wholly owned subsidiary Diamond Anvil Designs has produced an updated, improved prototype of its new vapor pen product.
Why GW Pharmaceuticals (GWPH) Stock Is Up Today
at The Street - Mon Apr 28, 2:01PM CDT
GW Pharmaceuticals (GWPH) is up after announcing that its Sativex drug received a fast track designation from the FDA.
Financial Press: Fields of Green
ACCESSWIRE - Mon Apr 28, 12:29PM CDT
Thelon Capital to Provide Infrastructure, Products, Expertise to Medical Marijuana Market
CannabisFN Weekly: Stock Move Lower as Valuations Start to Normalize
ACCESSWIRE - Mon May 12, 8:34AM CDT
WHITEFISH, MT / MAY 12, 2014 / The Marijuana Index(TM) moved lower last week, led by steep declines in CannaVEST Corp. (OTC: CANV) and modest declines in bellwethers like GW Pharmaceuticals plc (NASDAQ: GWPH) and MedBox Inc. (OTC: MDBX).
Research & Development Kick Into High Gear For Cannabis Based Medicine - New Collaboration Agreement For Development of Cannabis Based Skin Cancer Medicine
PR Newswire - Fri May 09, 7:50AM CDT
Marijuana & Cannabinoid Based Medicine industry continues to grow as companies forge ahead searching for new research and development, as well as expansion, opportunities: New Colombia Resources, Inc. (OTC: NEWC), GW Pharmaceuticals plc (NASDAQ: GWPH), Hemp, Inc. (OTC: HEMP), Nuvilex, Inc. (OTC: NVLX) and Tranzbyte Corporation (OTC: ERBB)
GW Pharmaceuticals to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
GlobeNewswire - Thu May 08, 11:00AM CDT
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group"
, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas, NV on Tuesday, 13 May, 2014 at 4:20 p.m. PT (1:20 p.m. ET). The conference will be held at the Encore at Wynn Las Vegas. FDA approves GW drug trial
at Investor's Business Daily - Wed May 07, 6:00PM CDT
The biotech reported a rise in revenue in the 6 months ended March 31. It posted a loss in profit vs. a gain in the 6-month period a year ago. GW Pharmaceuticals (GWPH) got Investigational New Drug status from the FDA for a Phase 2/3 clinical trial...
Today’s Top Biotech Stories: Aegerion, GW, and Ariad Pharmaceuticals
Leo Sun, The Motley Fool - Motley Fool - Wed May 07, 8:11AM CDT
Let's take a closer look at three stocks -- Aegerion Pharmaceuticals , GW Pharmaceuticals , and Ariad Pharmaceuticals -- which could make waves across the health care sector this Wednesday morning. Aegerion slumps on weak earnings...
GW Pharmaceuticals plc Reports Second Quarter 2014 Financial Results and Operational Progress
GlobeNewswire - Wed May 07, 4:06AM CDT
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group"
, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial results for the second quarter and half year ended 31 March 2014. GW Pharmaceuticals Receives Investigational New Drug (IND) From FDA for Phase 2/3 Clinical Trial of Epidiolex(R) in the Treatment of Dravet Syndrome
GlobeNewswire - Wed May 07, 4:06AM CDT
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group"
, a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the Company has received confirmation from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug application (IND) is now open for Epidiolex in the treatment of Dravet Syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy. GW expects to commence a Phase 2/3 clinical trial in the second half of 2014. BreedIT Corp: The Money is in the Seeds
ACCESSWIRE - Tue May 06, 8:52AM CDT
Whitefish, MT / May 6, 2014 / The U.S. cannabis industry is expected to grow more than five-fold over the next five years, from $2.2-2.6 billion in 2014 to an estimated $7.4-8.2 billion by 2018, according to new report by MMJ Business Daily. While growers and dispensaries will likely take the lion's share of the revenue, the highest margin opportunities may be in licensing the seeds used to grow specific optimized strains.
GW Pharmaceuticals Appoints Dr. Kenneth Sommerville as VP, Clinical Science
GlobeNewswire - Tue May 06, 1:00AM CDT
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group"
, a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced the appointment of Kenneth Sommerville MD to the newly created position of VP, Clinical Science, based in the United States. CannabisFN Weekly: New Rules for Edibles Signal Maturing Market
ACCESSWIRE - Mon May 05, 8:02AM CDT
Whitefish, MT / May 5, 2014 / The Marijuana Index™ moved about 8% higher over the past week, led by a 15% jump in GW Pharmaceuticals plc (NASDAQ: GWPH) shares. Last week, Morgan Stanley analysts rated the stock "overweight" with a $103.00 per share price target, which is significantly higher than the consensus price target of $54.43. Shares of many other cannabis stocks remained largely neutral throughout the week.
Earnings Results, Acquisitions, Drug Designations, Dividend Authorizations, and Licensing Agreements - Analyst Notes on AstraZeneca, Furiex, GW, Techne and Agenus
PR Newswire - Mon May 05, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding AstraZeneca PLC (NYSE: AZN), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX), GW Pharmaceuticals plc (NASDAQ: GWPH), Techne Corp. (NASDAQ: TECH) and Agenus Inc. (NASDAQ: AGEN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1869-100free.
Jim Cramer's Top Stock Picks: PNRA GWPH LOCK
at The Street - Sat May 03, 5:00AM CDT
Cramer has a taste for the improvements at Panera, is high on GW Pharmaceuticals and thinks LifeLock cheap stock is a steal.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri May 02, 7:24PM CDT
Today's move into the red caught investors by surprise because the economy seems to be improving. Here's what Cramer will be watching next week.
3 Stocks Spiking on Big Volume
at The Street - Thu May 01, 8:23AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
GW Pharmaceuticals to Report Q2 2014 and Half Year Financial Results and Host Conference Call on 7 May, 2014
GlobeNewswire - Tue Apr 29, 11:30AM CDT
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"
, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 7 May, 2014 its second quarter and half year financial results for the period ending 31 March, 2014. GW will also host a conference call the same day at 1:00 p.m. BST (8:00 a.m. EDT). Jim Cramer's Stop Trading: The Go-To Medical Marijuana Stock
at The Street - Tue Apr 29, 10:29AM CDT
A new study says medical marijuana has benefits for patients with multiple sclerosis, and Cramer says the go-to stock in this area is GW Pharmaceuticals.
Autism Patients Could Be Helped with Cannabis
at The Street - Tue Apr 29, 7:30AM CDT
GW Pharmaceuticals hasn't pursued the autism patient population with its cannabis drugs, but impatient parents may not want to wait.
NTRR Prepares to Bring New Products Online
Business Wire - Tue Apr 29, 4:00AM CDT
After extensive testing and feedback from potential distributors and users this month at mega-events Cannabis Cup and the Big Industry Show in Colorado, Neutra Corp. (OTCBB: NTRR) announced today that its wholly owned subsidiary Diamond Anvil Designs has produced an updated, improved prototype of its new vapor pen product.
Why GW Pharmaceuticals (GWPH) Stock Is Up Today
at The Street - Mon Apr 28, 2:01PM CDT
GW Pharmaceuticals (GWPH) is up after announcing that its Sativex drug received a fast track designation from the FDA.
Financial Press: Fields of Green
ACCESSWIRE - Mon Apr 28, 12:29PM CDT
Thelon Capital to Provide Infrastructure, Products, Expertise to Medical Marijuana Market
